Heart failure & cardiomyopathiesSecondary analysis
Finerenone in Patients With a Recent Worsening Heart Failure Event
- Secondary analysis of the FINEARTS-HF randomised trial
- double-blind
- placebo-controlled
- prespecified analysis
Authors' conclusion
Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death
Study context
- Population
- Patients with heart failure (HF) and LVEF ≥40%validly randomised
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo, by time from worsening heart failure (WHF) event to randomisation
- Primary endpoint
- Composite of:
- Total (first and recurrent) WHF events
- Cardiovascular (CV) death
Primary result
As reported in the abstract
Primary composite by time from WHF (subgroups)
Finerenone vs PlaceboRelative risk (95% CI)
within 7 days of WHF
0.74(0.57–0.95)
7 days to 3 months of WHF
0.79(0.64–0.97)
>3 months from WHF or no prior WHF
0.99(0.81–1.21)
- Greater absolute risk reductions with finerenone in recent WHF
- P for trend = 0.011
Further findings
| Outcome | RR (95% CI) | |
|---|---|---|
| Primary composite risk, during/within 7 days of WHF vs >3 months or no prior WHF | 2.13 (1.82–2.55) | |
| 0.20.5125Relative risk (log scale) |
Safety
Adverse events incl. hyperkalemia and worsening renal function with finerenone
- Not increased in those with recent WHF
Original publication
Finerenone in Patients With a Recent Worsening Heart Failure Event. J Am Coll Cardiol. Published 29 September 2024. doi:10.1016/j.jacc.2024.09.004
Summarised from the published abstract; every number is checked against it